2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
4
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Rheumatoid Arthritis, Systemic Juvenile
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Periodic Fevers Syndrome
1
Pancreatic Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mevalonate Kinase Deficiency
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma
1
Leukemia, Myelomonocytic, Chronic
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Clonal Cytopenia of Undetermined Significance
1
Carcinoma, Renal Cell
1
Carcinoma, Ductal
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Arthritis, Juvenile
1
Arthralgia
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sunitinib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
canakinumab
×
Clear all
NCT03626545
2023-08-21
CANOPY-2
Novartis
Phase 3
Terminated
245 enrolled
29 charts